Adverse Events Associated with Radium-223: Disproportionality Analysis of FDA Data Reflecting Worldwide Utilization

被引：0
|
作者：
Huynh-Le, M. P. [1 ]
Shults, R. C. [1 ]
Connor, M. [1 ]
Hattangadi-Gluth, J. A. [1 ]
机构：
[1] Univ Calif San Diego, La Jolla, CA 92093 USA
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2019年 / 105卷 / 01期
关键词：
D O I：
10.1016/j.ijrobp.2019.06.1315
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3298
引用
收藏
页码：E562 / E562
页数：1
相关论文
共 50 条
  • [21] Novel adverse events of blonanserin: a disproportionality analysis in the FDA Adverse Event Reporting System database
    Subeesh, Viswam
    Singh, Hemendra
    Maheswari, Eswaran
    Beulah, Thomas
    MINERVA PSICHIATRICA, 2018, 59 (02): : 105 - 110
  • [22] Gastrointestinal adverse events associated with PI3K inhibitors: A disproportionality analysis of FDA adverse event reporting system
    Viswam, Subeesh Kulangara
    Kamath, Raksha
    Sharon, Jovita
    Shivakumar, Adithya
    Shenoy, Anjana
    Lukose, Lipin
    Kaur, Gursimran
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2022, 31 : 454 - 455
  • [23] Role of radium-223 discontinuation due to adverse events in castration-resistant prostate cancer patients. A retrospective monocentric analysis
    Turco, Fabio
    Tucci, Marcello
    Angusti, Tiziana
    Parente, Antonella
    Di Stefano, Rosario Francesco
    Urban, Susanna
    Pisano, Chiara
    Samuelly, Alessandro
    Audisio, Alessandro
    Audisio, Marco
    Parlagreco, Elena
    Ungaro, Antonio
    Scagliotti, Giorgio Vittorio
    Di Maio, Massimo
    Buttigliero, Consuelo
    TUMORI JOURNAL, 2023, 109 (02): : 233 - 243
  • [24] Novel Adverse Events of Bevacizumab in the US FDA Adverse Event Reporting System DatabaseA Disproportionality Analysis
    Behrooz K. Shamloo
    Pankdeep Chhabra
    Andrew N. Freedman
    Arnold Potosky
    Jennifer Malin
    Sheila Weiss Smith
    Drug Safety, 2012, 35 : 507 - 518
  • [25] Adverse events related to neuromuscular blocking agents: a disproportionality analysis of the FDA adverse event reporting system
    Li, Liangxia
    Xu, Qianqian
    Liu, Yarui
    Pang, Liangfang
    Cui, Zhou
    Lu, Yuanyuan
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [26] Novel Adverse Events of Bevacizumab in the US FDA Adverse Event Reporting System Database A Disproportionality Analysis
    Shamloo, Behrooz K.
    Chhabra, Pankdeep
    Freedman, Andrew N.
    Potosky, Arnold
    Malin, Jennifer
    Smith, Sheila Weiss
    DRUG SAFETY, 2012, 35 (06) : 507 - 518
  • [27] Disproportionality analysis of adverse events associated with asfotase alfa: a post-marketing study using the FDA Adverse Event Reporting System
    Wang, Wen
    Wang, Zhe
    Chen, Qianxiu
    Sun, Haixia
    Fu, Zongchao
    Han, Jing
    Lv, Hao
    EXPERT OPINION ON DRUG SAFETY, 2024,
  • [28] A DISPROPORTIONALITY ANALYSIS OF THE SERIOUS ADVERSE DRUG EVENTS ASSOCIATED WITH GENE THERAPY PRODUCTS USING THE FDA ADVERSE EVENT REPORTING SYSTEM (FAERS)
    Ghanem, B.
    Fleming, M.
    Brown, L. M.
    Rodriguez-Monguio, R.
    Seoane-Vazquez, E.
    VALUE IN HEALTH, 2023, 26 (06) : S237 - S237
  • [29] A Disproportionality Analysis of the Adverse Drug Events Associated with Lurasidone in Paediatric Patients Using the US FDA Adverse Event Reporting System (FAERS)
    Rees, Kate E.
    Chyou, Te-yuan
    Nishtala, Prasad S.
    DRUG SAFETY, 2020, 43 (06) : 607 - 609
  • [30] Ocular adverse events associated with BRAF and MEK inhibitor combination therapy: a pharmacovigilance disproportionality analysis of the FDA adverse event reporting system
    Huang, Shuohan
    Guo, Zihan
    Wang, Mengmeng
    She, Youjun
    Ye, Xuan
    Zhai, Qing
    Liu, Jiyong
    Du, Qiong
    EXPERT OPINION ON DRUG SAFETY, 2023, 22 (02) : 175 - 181
12345